12th Edition of International Conference on
Neurology and Neurological Disorders
June 22-24, 2026 | Barcelona, Spain
Psychiatric and Behavioral Disorders
The complexity of psychiatric and behavioral disorders stems from their multifaceted nature, which affects mood, cognition, and behavior in diverse ways. Disorders like depression, anxiety, and schizophrenia are often influenced by a combination of genetic predisposition, environmental factors, and neurochemical imbalances. Advances in neuroimaging and molecular genetics are allowing researchers to explore the structural and functional brain changes associated with these conditions, offering new opportunities for targeted therapies. Current treatment strategies, including medications and psychotherapy, aim to alleviate symptoms and improve patient quality of life. As research progresses, personalized approaches to mental health care, based on an individual's genetic makeup and environmental influences, are emerging as a promising pathway to more effective treatments.
Ken Ware
NeuroPhysics Therapy Institute, Australia
Robert B Slocum
University of Kentucky HealthCare, United States
Yong Xiao Wang
Albany Medical College, United States
Milton Cesar Rodrigues Medeiros
Hospital Santa Casa de Arapongas, Brazil
Zhenhuan Liu
Guangzhou University of Chinese Medicine, China
Jaqueline Tuppen
COGS Club, United Kingdom
Luiz Moutinho
University of Suffolk, United KingdomSubmit your abstract Today
Title : Perception and individuality in patient cases identifying the ongoing evolution of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
Ken Ware, NeuroPhysics Therapy Institute, Australia
Title : Narrative medicine: A communication therapy for the communication disorder of Functional Seizures (FS) [also known as Psychogenic Non-Epileptic Seizures (PNES)]
Robert B Slocum, University of Kentucky HealthCare, United States
Title : Personalized and Precision Medicine (PPM), as a unique healthcare model through biodesign-driven biotech and biopharma, translational applications, and neurology-related biomarketing to secure human healthcare and biosafety
Sergey Victorovich Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Neuro sensorium
Luiz Moutinho, University of Suffolk, United Kingdom
Title : GBF1 inhibition reduces amyloid-beta levels in viable human postmortem Alzheimer's disease cortical explant and cortical organoid models
Sean J Miller, Yale School of Medicine, United States
Title : Traumatic Spinal Cord Injuries (tSCI) - Are the radiologically based “advances” in the management of the injured spine evidence-based?
W S El Masri, Keele University, United Kingdom